Acer Therapeutics Lands $8,150,000 Series B Financing

  • Feed Type
  • Date
    5/11/2016
  • Company Name
    Acer Therapeutics
  • Mailing Address
    222 Third Street Cambridge, MA 02142 USA
  • Company Description
    Acer Therapeutics is developing therapies with established clinical proof-of-concept for the treatment of serious, ultra-rare diseases with critical unmet medical need.
  • Website
    http://www.acertx.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $8,150,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    Proceeds from the financing will primarily be used to prepare a new drug application (NDA) for the company’s lead candidate, ACER-002 (celiprolol hydrochloride), which is being developed for the treatment of vascular Ehlers-Danlos Syndrome (vEDS), a rare, life-threatening genetic connective tissue disorder.
  • M&A Terms
  • Venture Investor
    TVM Capital
  • Venture Investor
    Undisclosed

Trending on Xconomy